Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 48, 2036-2041, April 15, 1988]
© 1988 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lorico, A.
Right arrow Articles by D'Incalci, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lorico, A.
Right arrow Articles by D'Incalci, M.

Accumulation of DNA Strand Breaks in Cells Exposed to Methotrexate or N10-Propargyl-5,8-dideazafolic Acid1

Aurelio Lorico2, Giuseppe Toffoli, Mauro Boiocchi, Eugenio Erba, Massimo Broggini, Germana Rappa and Maurizio D'Incalci

Division of Experimental Oncology 1, Centro di Riferim. Oncologico, Aviano, PN [A. L., G. T., M. Bo., G. R.], and Istituto di Ricerche Farmacologiche "Mario Negri," Milan [E. E., M. Br., M. D.], Italy

N10-Propargyl-5,8-dideazafolic acid (CB 3717), a new antifolate which directly inhibits thymidylate synthase and which is now under early clinical investigation, was compared with methotrexate (MTX) for its antiproliferative activity and mode of action on M14 human melanoma cell line and NIH/3T3 murine fibroblasts transfected with human c-Ha-ras oncogene (NIH/3T3R). CB 3717 was as active as MTX on both cell lines in inhibiting colony formation, but 20–100 times less potent. After 24 h of exposure both drugs caused an accumulation of cells in the G1 phase of the cell cycle, probably because of inhibition of DNA synthesis and blockage at the G1-S boundary. In NIH/3T3R treated for 16 h with 2 µM MTX or 200 µM CB 3717, we found DNA single-strand breaks amounting to approximately 130 and 140 rad equivalents, respectively, and a considerable number of DNA double-strand breaks, far more than expected if they had been the result of the proximity of single-strand breaks on the two complementary DNA strands. No DNA-protein cross-links were detected. When cells were incubated in drug-free medium for 8 h, there was a further accumulation of single-strand breaks, possibly due to the effects of the drug retained intracellularly as polyglutamyl derivative. Simultaneous treatment with 1.77 µM cycloheximide prevented DNA damage produced by both drugs. Thymidine (10 µM), renewed in the culture medium every 24 h, also prevented DNA damage and cytotoxicity. Since after 16 h treatment with MTX or CB 3717 cells were completely viable, as assessed by [3H]thymidine release, trypan blue exclusion test, and 51Cr release, DNA damage appears to be an early event preceding cell death and may be a feature of the killing ability of the drugs. The involvement of a protein in the formation of DNA breaks is suggested by the fact that when protein synthesis was inhibited with cycloheximide DNA damage was no longer seen.

1 The study was partially supported by the Italian Association for Cancer Research and by the Italian National Research Council, Rome, Italy, Progetto Oncologia Np. 86.00653.44.

2 To whom requests for reprints should be addressed, at Division of Experimental Oncology 1, Centro di Riferim. Oncologico, 33081 Aviano, PN, Italy.

Received 12/10/86. Revised 6/30/87. Revised 11/16/87. Accepted 12/22/87.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J. L. Bronder and R. G. Moran
A Defect in the p53 Response Pathway Induced by de Novo Purine Synthesis Inhibition
J. Biol. Chem., December 5, 2003; 278(49): 48861 - 48871.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
L. A. Parsels, R. C. Zellars, T. L. Loney, J. D. Parsels, M. F. Clarke, A. K. Merchant, T. S. Lawrence, and J. Maybaum
Prevention of Fluorodeoxyuridine-Induced Cytotoxicity and DNA Damage in HT29 Colon Carcinoma Cells by Conditional Expression of Wild-Type p53 Phenotype
Mol. Pharmacol., October 1, 1997; 52(4): 600 - 605.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Chow and H. Rubin
Ubiquitous, heritable damage in cell populations that survive treatment with methotrexate
PNAS, August 5, 1997; 94(16): 8773 - 8778.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1988 by the American Association for Cancer Research.